TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06765980: A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

Sponsor: Kriya Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 62 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$338,640

Rescue Site Savings

+$225,760

Unlock Full NCT06765980 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06765980 Rescue Dossier →